sugammadex
Phase 3Completed 0 watching 0 views this week๐ Rising
77
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Anesthesia
Conditions
Anesthesia
Trial Timeline
Sep 24, 2008 โ Mar 15, 2010
NCT ID
NCT00702715About sugammadex
sugammadex is a phase 3 stage product being developed by Merck for Anesthesia. The current trial status is completed. This product is registered under clinical trial identifier NCT00702715. Target conditions include Anesthesia.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (9)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05276804 | Phase 3 | Completed |
| NCT03196167 | Approved | Completed |
| NCT02011490 | Phase 1 | Completed |
| NCT00826176 | Phase 3 | Completed |
| NCT00702715 | Phase 3 | Completed |
| NCT00535496 | Phase 3 | Completed |
| NCT00591786 | Phase 2 | Completed |
| NCT00552929 | Phase 2 | Completed |
| NCT00482599 | Phase 3 | Completed |
Competing Products
20 competing products in Anesthesia